Cary Street Partners Financial LLC Invests $228,000 in GSK plc (NYSE:GSK)

Cary Street Partners Financial LLC acquired a new position in shares of GSK plc (NYSE:GSK) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,731 shares of the pharmaceutical company’s stock, valued at approximately $228,000.

A number of other hedge funds have also bought and sold shares of the company. Dodge & Cox raised its position in shares of GSK by 0.5% in the 4th quarter. Dodge & Cox now owns 68,440,912 shares of the pharmaceutical company’s stock worth $2,314,672,000 after acquiring an additional 353,749 shares in the last quarter. FMR LLC increased its holdings in GSK by 82.1% in the fourth quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company’s stock worth $1,786,475,000 after purchasing an additional 23,814,104 shares in the last quarter. Primecap Management Co. CA lifted its stake in GSK by 70.1% in the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company’s stock valued at $854,349,000 after buying an additional 10,407,905 shares during the period. Fisher Asset Management LLC boosted its holdings in shares of GSK by 1.4% during the 4th quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company’s stock worth $637,061,000 after buying an additional 259,867 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of GSK by 0.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,566,922 shares of the pharmaceutical company’s stock worth $255,914,000 after buying an additional 35,134 shares during the period. Institutional investors own 15.74% of the company’s stock.

Wall Street Analysts Forecast Growth

GSK has been the topic of a number of research reports. BNP Paribas began coverage on shares of GSK in a research report on Tuesday, April 15th. They set a “neutral” rating and a $35.25 target price on the stock. Hsbc Global Res upgraded shares of GSK to a “strong sell” rating in a report on Monday, April 28th. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Thursday, April 24th. Finally, Morgan Stanley began coverage on GSK in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. One analyst has rated the stock with a sell rating, eight have given a hold rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $40.58.

GSK Stock Down 0.7 %

Shares of NYSE:GSK opened at $36.63 on Friday. The business’s 50 day moving average is $37.65 and its 200 day moving average is $35.99. GSK plc has a 12-month low of $31.72 and a 12-month high of $45.93. The stock has a market cap of $75.58 billion, a price-to-earnings ratio of 23.04, a PEG ratio of 1.12 and a beta of 0.51. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.05. The firm had revenue of $10.06 billion for the quarter, compared to the consensus estimate of $7.52 billion. GSK had a net margin of 8.13% and a return on equity of 48.59%. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.43 EPS. On average, sell-side analysts forecast that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be paid a $0.4216 dividend. This is a positive change from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, May 16th. This represents a $1.69 annualized dividend and a yield of 4.60%. GSK’s dividend payout ratio (DPR) is 86.60%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.